📰 Eva Kalias News
Page 5 - Eva Kalias News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eva Kalias. Real-time updates on events, politics, business and more.
June 10, 2022
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST, 13:30 BST, 08:30 EDT. Details are at the end of this statement. Revenue from contracts with customers
June 10, 2022
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne mus...
June 9, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 9, 2022
Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular
June 4, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 3, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Corporate Calendar Update
June 3, 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 3, 2022 -- Santhera Pharmaceuticals (SIX: SANN) has updated its corporate calendar. The Company will publish its 2021 Annual Report
June 2, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Improved Liquidity Position
June 2, 2022
Ad hoc announcement pursuant to Art. 53 LR Restructured timing of ReveraGen milestone payments, reducing near-term liquidity needsSecured up to CHF 40 million of additional financing
March 15, 2022
Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone